Article

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer

2023-03-23

Abstract excerpt

<title>Abstract</title> <p>Kirsten rat sarcoma viral oncogene homologue (KRAS) is a frequent oncogenic driver of solid tumors, including non-small cell lung cancer (NSCLC). Its treatment and outcomes have been dramatically revolutionized by direct targeted therapies because of the lack of deep binding pockets for specific small -molecule inhibitors. Here, we demonstrated that the class III histone deacetylase SIR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a60f0376-66a5-5dcf-ad83-7eaf316039db
DOI: 10.21203/rs.3.rs-2607291/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancerDOI 10.21203/rs.3.rs-2607291/v1Read

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.Semantic proximity Read

Targeting TGF-β-Smad2/3-JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancerSemantic proximity Read

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.Semantic proximity Read

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Semantic proximity Read

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.Semantic proximity Read

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read

SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status.Semantic proximity Read

The KRAS G12C mutation in NSCLC: from target to resistanceSemantic proximity Read

Sirt1 protects from K-Ras-driven lung carcinogenesis.Semantic proximity Read

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.Semantic proximity Read

New Horizons in KRAS-Mutant Lung Cancer: Dawn After DarknessSemantic proximity Read

Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer.Semantic proximity Read